Roche Pharma India Launches MS Drug

New Delhi: Roche Pharma India has launched a drug for the treatment of Multiple Sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of patients grappling with the disease.

The company has introduced Ocrevus (Ocrelizumab) which is the first and only approved disease modifying therapy for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).

Patients on Ocrevus have the highest persistence and superior adherence to treatment because of its twice yearly (once every six months) dosing which is preferable for most patients compared to more frequent (monthly) injections.

"The introduction of Ocrevus represents a pivotal moment in the management of multiple sclerosis in India," Roche Pharma India CEO and Managing Director V Simpson Emmanuel said.

Boasting formidable efficacy, streamlined administration, and a long-term safety record, Ocrevus instils fresh optimism in individuals grappling with this formidable neurological condition, he added.

The majority of individuals are diagnosed with multiple sclerosis between the ages of 20 and 40, making the disease a leading cause of non-traumatic disability in younger adults.

Read also:

• Roche Xolair gets USFDA nod for children, adults with one or more food allergies
• Roche receives USFDA Breakthrough Device Designation for Multiple Sclerosis test Elecsys NfL

The team had earlier reported that Roche's Elecsys Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) had received Breakthrough Device Designation from the USFDA.